3SOF

Profile:  


Vanda Pharmaceuticals, Inc.
9605 Medical Center Drive
Suite 300
Rockville, MD 20850
United States - Map
Phone: 240-599-4500
Fax: 301-294-1900
Web Site: http://www.vandapharmaceuticals.com

DETAILS  
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 50


BUSINESS SUMMARY  
Vanda Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. Its product portfolio includes Fiapta, a compound for the treatment of schizophrenia and bipolar disorder; VEC-162, a compound for the treatment of sleep and mood disorders; and VSF-173, a compound for the treatment of excessive sleepiness. The company was founded in 2002 and is headquartered in Rockville, Maryland.

One to watch... Ready to MOVE 
Coming off a 52-week low, volume has heated up.
Today, Vanda Pharmaceuticals Inc. topped the list of Biggest Percentage Price Gainers on the Nasdaq Stock Market.

52wk Range: 2.70 - 22.49
Volume: 4,798,841
Avg Vol (3m): 467,176

Shares of Vanda Pharmaceuticals
Surge on Positive Comments from Analysts
Shares of Vanda Pharmaceuticals Inc. (VNDA) surged on heavy volume
today after positive comments from analysts on Friday. Caris & Co
initiated coverage of VNDA at Buy with a target price of $22. The firm
said,"VNDA has been on a tumultuous ride over the past 24 months,
with many current disbelievers in the company's pipeline, particularly on
its lead compound, Fanapta, under FDA review for schizophrenia. The
firm's analysis on Fanapta's safety and efficacy leads to our belief that
the risk/benefit profile of the product is favorable, and that the FDA will
see it that way, with a U.S. regulatory decision set for late July." JPMorgan
forecast peak sales of $400 million for Fanapta. The firm reiterated
its overweight rating, saying it believed VNDA "offers a compelling and
underappreciated investment opportunity." The firm continued, "We are
positive on the prospects for both Fanapta and VEC-162, an insomnia
treatment entering Phase III trials, as both drugs appear to be differentiated
in large therapeutic markets. The commercial opportunity for both
products remains robust and far exceeds the current market valuation
of about $95 million." Banc of America also said it expects Fanapta to
be approved and said Vanda "should have sufficient cash" to launch
the drug.
Nam Tai Electronics Reduces
Mobile Reliance to Achieve Higher Margins
Trading on Nam Tai Electronics, Inc. (NTE) was down 9.785% following
this morning earnings call in which the company reported Q1 revenues
of $147.13M, down 23.20% from last year and missing consensus by
10.18%. Q1 EPS was $.17. Adjusted Q1 EPS was $.19, up 18.75%
from last year and beating consensus by 11.76%. During the call, the
company reported that manufactured higher gross margin products due
to its objective in diversifying into other areas of business. In 2006, the
majority of revenues was in the mobile phone range. However, in Q1,
reliance in the mobile space fell below 59%. Nam Tai is also antipciating
a tough year in the global economic environment, and will be cautious
on cap ex while pushing productivity. The company also does not expect
a sequential decline in OEM inventory for handsets, but does expect
marginal growth in the next quarter. Said the company, "We have not
lost any customers or major programs, its just a function of our customers
pushing out product or canceling orders based on their own demand."
With cap-ex coming in low for last quarter, the numbers this year are
$90M for this year and $80M for next. However, the company believes
it's possible it could shift some of the $90M into 2009 if it doesn't see
demand improving in the next quarters.

Did anyone see.... 

BIOTECH STOCKS
Titan, Vanda rocket on FDA approval

VNDA 7.84, +6.76, +625.9%) rocketed more than 600% to $8.11.
Late Wednesday, Vanda announced that the Food and Drug Administration has approved its schizophrenia medication Fanapt. The agency had rejected the product last year, stating it needed more supporting data.

Fanapt was co-developed with Titan Pharmaceuticals (TTNP:Titan Pharmaceuticals Inc
TTNP.PK  0.80, +0.75, +1500.0%) , which is in the process of selling its assets. Shares of Titan rocketed more than1,400% to 77 cents.

Vanda Snaps Victory From The Jaws Of Defeat...

Vanda shares peak after Fanapt gets FDA approval
FDA approves Vanda Pharmaceuticalss schizophrenia drug, and stock rockets in heavy trading
On Thursday May 7, 2009, 3:41 pm EDT

NEW YORK (AP) -- Shares of Vanda Pharmaceuticals Inc. surged Thursday after the Food and Drug Administration approved Vanda's schizophrenia drug Fanapt, following a delay of more than nine months.

In July, Vanda said the agency declined to approve Fanapt. It asked Vanda to compare the drug to a similar product, like risperidone, and also requested new safety data. That news sent Vanda shares plunging, and Thursday, they more than recovered from their losses.

In afternoon trading, the stock advanced $6.40, to $7.48. Earlier it peaked at $10, its highest level since November 2007. More than 9 million shares changed hands, which is far above the stock's 100-day average of 122,000 shares.

Vanda said Fanapt may have safety advantages over similar drugs, pointing to the fact that among trial patients, rates of tremors, restlessness, and weight gain were low, and no elevation in cholesterol or triglycerides were seen.

Vanda said it expects to start shipping the drug later this year. The company said it will consider a partnership in bringing Fanapt to market, but will look at other options as well.

In a note to clients, Natixis Bleichroeder analyst Corey Davis said the decision was "one of the most surprising moves we've seen out of the FDA this year." He said Fanapt should have patent protection until 2016 or 2017, and doctors may be willing to switch patients on other drugs over to Fanapt.

He also wrote that Fanapt "arguably has one of the most benign safety profiles of all the (atypical antipsychotic drugs) out there," comparing it treatments like risperidone. Davis upgraded Vanda stock to "buy" from "hold," and lifted his price target to $12 per share from $1.

After Vanda announced the approval, the company said Tang Capital Partners ended its attempt to gain control of Vanda and liquidate it. Tang withdrew a slate of candidates for Vanda's board, halting a proxy contest.

updated chart look...

52wk Range: 0.45 - 10.00
Volume: 6,477,749
Avg Vol (3m): 365,138

Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
156.78%above 13-day MA
457.64%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $225.62 
P/E Ratio: N/A 
PEG Ratio: N/A 
Next Earnings: 08/04/2009
Last Analyst Rating: Neutral

updated chart look...

VNDA...Strong Uptrend !